Stocks Health care PLX
NYSE · Health careProtalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. brought in $80.6M of revenue over the twelve months to June 30, 2026, up 30.1% from a year earlier. Net income was $18.9M, a net margin of 23.5%. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At June 30, 2026 it held $27.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Protalix BioTherapeutics, Inc.
- Net worth
- Protalix BioTherapeutics, Inc. has a market value (market cap) of $205.5M at the latest share price, and shareholders' equity of $71.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $52.7M (-1.2% year on year), with a net loss of $6.6M. Over the 12 months to June 30, 2026: revenue $80.6M, net income $18.9M.
- Cash flow
- In fiscal 2025 operations used $12M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Protalix BioTherapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Protalix BioTherapeutics, Inc. does
Protalix BioTherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker PLX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $52.7M | -$6.6M | -$0.08 | -$13.6M |
| 2024 | $53.4M | $2.9M | $0.04 | $7.4M |
| 2023 | $65.5M | $8.3M | $0.09 | -$2.5M |
| 2022 | $47.6M | -$14.9M | -$0.31 | -$25.6M |
| 2021 | $38.4M | -$27.6M | -$0.62 | -$11.7M |
| 2020 | $62.9M | -$6.5M | -$0.22 | -$26.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PLX ranks in Health care
Latest SEC filings
What Protalix BioTherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 15, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 27% to $19.9M versus the same quarter last year; diluted EPS $0.05 versus $0.00.
- August 12, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 25, 2026
- May 21, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 234% to $33.8M versus the same quarter last year; diluted EPS $0.22 versus -$0.05.
- May 13, 2026
- April 30, 2026
Insider trades
What the people running Protalix BioTherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| December 19, 2025 | Bashan DrorPRESIDENT AND CEO, Director | Bought | 56,000 | $101.4K |
| November 18, 2025 | Bar-Shalev AmosDirector | Sold | 168 | $314.2 |
Who owns PLX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| HOLD Alapkezelo Zrt.13G, passive | 5.2% | October 15, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 188,516 shares in total, about $480.7K at the last price.
| Holder | Shares |
|---|---|
| Bashan DrorPRESIDENT AND CEO, Director | 188,516 |
Questions about PLX
What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc. is a company in the Health care sector, listed on NYSE as PLX. Its shares trade on NYSE under the ticker PLX.
What is Protalix BioTherapeutics, Inc.'s net worth?
Protalix BioTherapeutics, Inc. has a market value (market cap) of $205.5M at the latest share price, and shareholders' equity of $71.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Protalix BioTherapeutics, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $18.9M on revenue of $80.6M, a net margin of 23.5%.
How much revenue does Protalix BioTherapeutics, Inc. make?
Over the twelve months to June 30, 2026 Protalix BioTherapeutics, Inc. reported revenue of $80.6M. That is 30.1% more than a year earlier.
When did Protalix BioTherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 15, 2026.
When is Protalix BioTherapeutics, Inc.'s next earnings report?
Protalix BioTherapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PLX with
Follow PLX
Get an email when Protalix BioTherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Protalix BioTherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.